Loading
A phase 2 trial of FPI-2265, Olaparib in prostate cancer, run by Fusion Pharmaceuticals Inc., active and no longer recruiting.
FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) is a phase 2 interventional study registered as NCT06909825 by Fusion Pharmaceuticals Inc., with 85 participants planned, started 2025-02-26 and due to reach its primary completion in 2027-05. Interventions recorded: FPI-2265, Olaparib. Conditions listed: Metastatic Castration-resistant Prostate Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares FPI-2265, Metastatic castration-resistant prostate cancer, AstraZeneca, Prostate cancer.
Shares PARP inhibitors, Olaparib, Metastatic castration-resistant prostate cancer, AstraZeneca.
Shares PARP inhibitors, Olaparib, AstraZeneca.
Shares FPI-2265, Metastatic castration-resistant prostate cancer, AstraZeneca, Prostate cancer.
Shares PARP inhibitors, Olaparib, AstraZeneca.
Shares PARP inhibitors, Olaparib, AstraZeneca.
Shares PARP inhibitors, Olaparib, AstraZeneca.
Shares FPI-2265, AstraZeneca, Prostate cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/